King v. DePuy Orthopaedics Incorporated

District Court, D. Arizona·Decided June 14, 2024·No. 2:23-cv-00196·Unknown

Opinion

WO

Michael King, et al., No. CV-23-00196-PHX-SMB

Plaintiffs, ORDER

v.

DePuy Orthopaedics Incorporated, et al.,

Defendants. Pending before the Court is Plaintiffs’ Motion to Strike Case-Specific Opinions of Scott D. Nelson, M.C., Ph.D. (Doc. 177). Defendants filed a response (Doc. 184), to which Defendants filed a reply (Doc. 187). For the reasons outlined below, the Court will grant Plaintiffs’ Motion to Strike. This Court has previously described the background of this case (Doc. 107) but for ease of reference will repeat it here. This case arose out of the installation of an allegedly defective “metal-on-metal” hip replacement manufactured, marketed, and sold by Defendants. This hip replacement is known as the Pinnacle Acetabular Cup System (hereinafter “device”). The device is used to replace diseased hip joints and was intended to remedy conditions such as osteoarthirits, rheumatoid arthritis, avascular necrosis, or fracture. It also sought to provide patients with pain-free natural motion over a longer period than other hip replacement devices. On June 28, 2010, Plaintiff Michael King underwent a total hip arthroplasty procedure in Mesa, Arizona and had the device implanted in his left hip. After the procedure, Plaintiff alleges that the friction between the cobalt-chromium components caused metal ions and particles to be released into his blood, tissue, and bone surrounding the implant, resulting in severe pain, discomfort, and inflammation. Because of his symptoms, Plaintiff underwent a second surgery to replace the device on January 10, 2014. Plaintiffs filed suit alleging negligence, strict liability, fraud, negligent misrepresentation, and breach of warranty claims. (See Doc. 17.) In addition, Mr. King’s wife, Deborah King, filed a loss of consortium claim. (See id.) The case was initially filed in the United States District Court for the Northern District of Texas as part of the multi- district litigation against Defendants coordinated out of that District. This case was not selected as one of the bellwether cases. See In re: DePuy Orthopaedics, Inc., MDL Docket No. 3:11-MD-2244-K, 2016 WL 6271474, at *1 (N.D. Tex. Jan. 5, 2016). Therefore, it was consolidated for purposes of discovery and pretrial matters. See id.; 28 U.S.C. § 1407. Litigation continued in the bellwether cases, resulting in substantial fact and expert discovery. As part of this discovery in September 2019 the MDL court entered Case Management Order (“CMO”) 12, which required Plaintiffs to issue notices to doctors and medical facilities to preserve treatment records including devices, tissue blocks and pathology blocks from five years before the surgery date. (Doc. 177-2.) Plaintiffs also had to provide Defendants with a list of entities/individuals who received a notice. (Id.) This CMO became effective for the first quarter of 2021, at which point Plaintiffs sent these preservation notices in May 2021. (Id.) In July 2021, Plaintiffs provided Defendants with Plaintiff King’s medical records, and the list of entities/individuals who received a preservation notice as the CMO required. (Doc. 177 at 4.) In November 2022, the parties produced their respective expert disclosures. (Id. at 5.) In December 2022, this case was transferred to the District of Arizona to be heard before this Court. (Doc. 41.) In February 2023, after this transfer, the parties appeared for a status conference to discuss, in part, expert witnesses. (Doc. 177-4 at 5.) There, Defendants informed the Court that their only case-specific expert would be Dr. Ebramzadeh. (Id.) The parties met again before this Court in August 2023 for a Daubert conference, again in October 2023 where Defendants’ motion to continue the trial was granted, and once more in in December 2023 for a status conference. (Id.) On April 15, 2024, the parties met for another status conference at which time the Court set the pre-trial deadlines. (Doc. 153.) Defendants did not mention any outstanding expert discovery. (Doc. 177 at 6.) However, on April 19, 2024, Defendants provided Plaintiffs with Dr. Nelson’s pathology report containing case-specific opinions regarding Plaintiff King’s injuries, and cause of injuries. (Doc. 177-5.) Defendants did notify Plaintiffs about the reason for delay at that time. (Id.) Plaintiffs now bring this Motion under Rule 26(a)(2) of the Federal Rules of Civil Procedure, asserting that the Court must strike Dr. Nelson’s case-specific opinions for failing to comply with the MDL and this Court’s scheduling orders. (Doc. 177 at 7.) Federal Rule of Civil Procedure 26(a)(2) provides, in relevant part: (A) In General. In addition to the disclosures required by Rule 26(a)(1), a party must disclose to the other parties the identity of any witness it may use at trial to present evidence under Federal Rule of Evidence 702, 703, or 705 . . . (C) Witnesses Who Do Not Provide a Written Report. Unless otherwise stipulated or ordered by the court, if the witness is not required to provide a written report, this disclosure must state: (i) the subject matter on which the witness is expected to present evidence under Federal Rule of Evidence 702, 703, or 705; and (ii) a summary of the facts and opinions to which the witness is expected to testify. Fed. R. Civ. P. 26(a)(2). “If a party fails to provide information or identify a witness as required by Rule 26(a) or (e), the party is not allowed to use that information or witness to supply evidence on a motion, at a hearing, or at a trial, unless the failure was substantially justified or harmless.” Fed. R. Civ. P. 37(c)(1); Cooke v. Town of Colorado City, No. CV 10-08105-PCT-JAT, 2013 WL 551508, at *3 (D. Ariz. Feb. 13, 2013). Litigants must disclose all expert witnesses “at the times and in the sequence that the court orders.” Merchant v. Corizon Health, Inc., 993 F.3d 733, 739 (9th Cir. 2021) (internal citation omitted.). Rule 37(c)(1) is an “automatic” sanction that prohibits the use of improperly disclosed evidence and—as stated by the rule—litigants may only avoid this sanction where “the failure [to disclose] was substantially justified or is harmless.” Id. at 740; Fed. R. Civ. P. 37(c)(1). This does not mean courts must impose the sanction, but rather that they are empowered to properly impose an exclusion sanction where the “noncompliant party has failed to show that the discovery violation was either substantially justified or harmless.” Merchant, 993 F.3d 733 at 740. Plaintiffs argue that the Court must strike Dr. Nelson’s case-specific opinions as untimely for failing to comply with the MDL and this Court’s scheduling orders. (Doc. 177 at 7.) Plaintiffs further argue that Defendants cannot show that their failure to comply with Rule 26 is “substantially justified or harmless” because (1) Defendants knew about the existence of pathological issues and still waited to file Dr. Nelson’s corresponding report; and (2) Plaintiffs are prejudiced by “their inability to adequately defend and rebut agai

Free access — add to your briefcase to read the full text and ask questions with AI

King v. DePuy Orthopaedics Incorporated, (D. Ariz. 2024).

King v. DePuy Orthopaedics Incorporated (King v. DePuy Orthopaedics Incorporated) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hoffman v. Construction Protective Services, Inc.
541 F.3d 1175 (Ninth Circuit, 2008)
Gary Merchant v. Corizon Health, Inc.
993 F.3d 733 (Ninth Circuit, 2021)
Liberty Insurance Corporation v. Yvonne Brodeur
41 F.4th 1185 (Ninth Circuit, 2022)